NI
PTGX icon

Numeric Investors’s Protagonist Therapeutics PTGX Stock Holding History

Numeric Investors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$558K Buy
+26,819
New +$476K ﹤0.01% 869

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Numeric Investors's PTGX Position: Q4 2017 in Review

Numeric Investors opened a new position in Protagonist Therapeutics (PTGX) in Q4 2017: 26,819 shares worth $558K. The stake represents ﹤0.01% of the portfolio and ranks #869 among its holdings.

66 funds tracked by Wall St. Rank hold PTGX as of Q4 2017.

  • Numeric Investors held 26,819 shares of Protagonist Therapeutics worth $558K as of Q4 2017.
  • Protagonist Therapeutics was a new Numeric Investors position in Q4 2017.
  • Protagonist Therapeutics made up ﹤0.01% of Numeric Investors's portfolio in Q4 2017, its #869 holding.
  • 66 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2017.

Based on Numeric Investors's 13F filing for Q4 2017, filed 14 Feb 2018.